Kamil Brzóska1, Teresa Bartłomiejczyk1, Barbara Sochanowicz1, Magdalena Cymerman1, Jacek Grudny2, Jacek Kołakowski3, Lucyna Kapka-Skrzypczak4, Marcin Kruszewski4, Paweł Sliwiński3, Kazimierz Roszkowski-Śliż2. 1. Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Warsaw, Poland. 2. Institute of Tuberculosis and Lung Diseases, Third Department of Lung Diseases, Warsaw, Poland. 3. Institute of Tuberculosis and Lung Diseases, Department of Diagnosis and Treatment of Respiratory Insufficiency, Warsaw, Poland. 4. Institute of Rural Health, Department of Molecular Biology and Translational Research, Lublin, Poland; University of Information Technology and Management, Faculty of Medicine, Department of Medical Biology and Translational Research, Rzeszów, Poland.
Abstract
INTRODUCTION AND OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is often accompanied by lung cancer. Among the genes that may play a role in the occurrence of COPD and lung cancer are those encoding the proteolytic enzymes, such as matrix metalloproteinases (MMPs) and their tissue inhibitors. The objective of this study was to find MMPs-associated markers useful in the identification of COPD subjects with increased susceptibility to developing lung cancer. MATERIALS AND METHODS: We compared the frequency of single nucleotide polymorphisms in genes coding for matrix proteinases (MMP1, MMP2, MMP3, MMP9, MMP12) as well as tissue inhibitor of metalloproteinases (TIMP1) in two groups of subjects: COPD patients (54 subjects) and COPD patients diagnosed for lung cancer occurrence (53 subjects).The levels of the respective proteins in blood serum were also analyzed. RESULTS: The frequencies of 2 genotypes, MMP3 rs3025058 and MMP3 rs678815, were significantly different between the studied groups. In both cases, more heterozygotes and less homozygotes (both types) were observed in the COPD group than in the COPD + cancer group. A significantly higher TIMP1 level in blood serum was observed in the COPD + cancer group than in the COPD group. There were no statistically significant differences in MMPs blood levels between the studied groups. In addition, no genotype-associated differences in TIMP1 or MMPs blood levels were observed. CONCLUSIONS: Homozygocity for MMP3 rs3025058 and rs678815 polymorphisms is a potential marker of enhanced susceptibility to lung cancer development among COPD subjects.
INTRODUCTION AND OBJECTIVE:Chronic obstructive pulmonary disease (COPD) is often accompanied by lung cancer. Among the genes that may play a role in the occurrence of COPD and lung cancer are those encoding the proteolytic enzymes, such as matrix metalloproteinases (MMPs) and their tissue inhibitors. The objective of this study was to find MMPs-associated markers useful in the identification of COPD subjects with increased susceptibility to developing lung cancer. MATERIALS AND METHODS: We compared the frequency of single nucleotide polymorphisms in genes coding for matrix proteinases (MMP1, MMP2, MMP3, MMP9, MMP12) as well as tissue inhibitor of metalloproteinases (TIMP1) in two groups of subjects: COPDpatients (54 subjects) and COPDpatients diagnosed for lung cancer occurrence (53 subjects).The levels of the respective proteins in blood serum were also analyzed. RESULTS: The frequencies of 2 genotypes, MMP3rs3025058 and MMP3rs678815, were significantly different between the studied groups. In both cases, more heterozygotes and less homozygotes (both types) were observed in the COPD group than in the COPD + cancer group. A significantly higher TIMP1 level in blood serum was observed in the COPD + cancer group than in the COPD group. There were no statistically significant differences in MMPs blood levels between the studied groups. In addition, no genotype-associated differences in TIMP1 or MMPs blood levels were observed. CONCLUSIONS: Homozygocity for MMP3rs3025058 and rs678815 polymorphisms is a potential marker of enhanced susceptibility to lung cancer development among COPD subjects.
Authors: Kamil Brzóska; Teresa Bartłomiejczyk; Barbara Sochanowicz; Magdalena Cymerman; Jacek Grudny; Jacek Kołakowski; Marcin Kruszewski; Paweł Śliwiński; Kazimierz Roszkowski-Śliż; Lucyna Kapka-Skrzypczak Journal: Oncol Lett Date: 2018-09-19 Impact factor: 2.967
Authors: Christopher Railwah; Alnardo Lora; Kanza Zahid; Hannah Goldenberg; Michael Campos; Anne Wyman; Bakr Jundi; Magdalena Ploszaj; Melissa Rivas; Abdoulaye Dabo; Susan M Majka; Robert Foronjy; Mohamed El Gazzar; Patrick Geraghty Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-09-23 Impact factor: 5.464
Authors: Paula M Maeda; Ana Paula S L Bicudo; Renata T M Watanabe; Thais S M Fonseca; Ricardo P do Souto; César E Fernandes; Emerson de Oliveira Journal: Eur J Obstet Gynecol Reprod Biol X Date: 2019-04-30